... specializing in Medicare plans (for seniors). The medical insurance sector has faced rising treatment costs this year, which could pressure profitability. Estimates for Humana in Q2 are mixed: revenue is expected at ~$31.8 billion (+8% year-on-year), while earnings per share will likely decrease – consensus is around $6.3, about 10-15% lower than last year. The reason is increased medical claims payouts due to deferred pandemic procedures and rising medical service costs. Investors will want to know if Humana will ...

... of the two largest global payment systems will report strong results for Q2, reflecting continued growth trends in cashless payments. Consensus forecasts suggest a revenue boost of ~14% year-on-year, reaching ~$8 billion, and an increase in adjusted earnings per share by about 12%, up to $4.00 (compared to $3.58 a year ago). Key drivers include high transaction volumes on Mastercard cards due to active consumer spending and travel: cross-border transactions and associated income from fees have been growing steadily ...

... were part of a pre-announced plan allowing Bezos to divest 25 million shares by the end of 2025, with approximately 22 million shares already sold. Investors may anticipate a new sales plan being announced, potentially in Amazon’s next quarterly report. Major Earnings Reports This Week: U.S. and Russia Monday, November 18 Pre-Market: MDMG (Mother and Child): Board of Directors to discuss ... ... +0.54%) Euro Stoxx 50 Futures: 4,810 (+5, +0.10%) S&P 500 Futures: 5,911.75 (+15.25, +0.26%) Commodities: Brent Oil: $71.39 per barrel (+$0.35, +0.49%) Natural Gas: $2.929 per MMBtu (+$0.106, +3.75%) Gold: $2,596.00 per ounce (+$25.90, +1.01%) Silver: ...

... growth rates. Eli Lilly (LLY): The pharmaceutical giant reported mixed results: revenue significantly exceeded expectations ($15.56 billion vs $14.7 billion), primarily due to high demand for diabetes and obesity medications (Mounjaro and others), but earnings per share ($5.60) disappointed market expectations ($6.30). Additional negativity came with news that a major US insurer (CVS) excluded the new drug Zepbound from its list, potentially limiting sales. As a result, Lilly shares fell by more than 14% – the ...

... confirming investors' confidence in the resilience of the US healthcare sector. Aon plc – the global giant in insurance and risk management showcased double-digit growth. Aon’s revenue in Q2 rose by 11% year-on-year (to $4.2 billion), and adjusted earnings per share increased by 19%, exceeding analysts’ forecasts. The company notes high demand for insurance brokerage and consulting services: despite market volatility, corporate clients continue investing in risk management. An additional growth factor was ...